The Many Roles of GLP-1 Receptor Agonists
  • CME
  • CE

How I use GLP-1 receptor agonists to manage patients with type 2 diabetes, and why they warrant broad use across multiple patient populations.
person default
Arthi Thirumalai, MBBS
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Registered Nurses: 0.25 Nursing contact hours
Released: December 18, 2020 Expiration: December 17, 2021

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Consider the key clinical evidence from CV outcomes trials with GLP-1 RAs in management decisions for patients with T2D
  • Differentiate the pharmacokinetic/pharmacodynamic characteristics and adverse event profiles of injection and oral GLP-1 RA products to optimize their use according to patient requirements and preferences

Acknowledgements

Provided by the Endocrine Society, in collaboration with Clinical Care Options.

For questions about content or obtaining CME credit, please contact the Endocrine Society at www.education.endocrine.org/contact.

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Novo Nordisk

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Arthi Thirumalai, MBBS

Assistant Professor
Division of Metabolism, Endocrinology and Nutrition
University of Washington
Seattle, WA

Arthi Thirumalai, MBBS, has disclosed that she has received funds for research support from Novo Nordisk.

Staff

Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran D. Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Anne Roc, PhD
Director, Scientific Services
Anne Roc, PhD, has no relevant conflicts of interest to report.
Julie Skowronski, FNP-BC
Julie Skowronski, FNP-BC, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for endocrinologists (physicians and fellows), internists, primary care physicians, endocrine nurses, and other advanced practice professionals who care for patients with T2D.

Goal

The goal of this activity is to improve the competence and performance of learners in leveraging the glycemic and extraglycemic properties of GLP-1 RA therapies to lower A1C, reduce comorbidity risks, and improve patient adherence and self-care in the management of T2D.

Physician Continuing Education

Accreditation

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.

The Endocrine Society designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

In support of improving patient care, this activity has been planned and implemented by The Endocrine Society and Clinical Care Options, LLC (CCO). Clinical Care Options, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hours.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 18, 2020, through December 17, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

CCO slides: patient-specific guidance on T2D treatment options and insights on managing CVD and CKD risk.

Anne Peters, MD Released: December 10, 2020

Get patient-specific guidance on T2D treatment options and insights on managing CVD and CKD risk, from Clinical Care Options (CCO)

Anne Peters, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Released: December 10, 2020 Expired: December 9, 2021

Enter type 2 diabetes patient characteristics in this online CCO tool and compare your treatment plan with those of 5 experts

Martin J. Abrahamson, MD, FACP Zachary T. Bloomgarden, MD, MACE Anne Peters, MD Richard E. Pratley, MD Robert S. Zimmerman, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: December 9, 2020 Expired: December 8, 2021

Vanita R. Aroda, MD, and Arthi Thirumalai, MBBS: from Endocrine Society and CCO. CME Webinar on GLP-1 RAs in T2D, including latest ADA and AACE guidelines

person default Vanita R. Aroda, MD person default Arthi Thirumalai, MBBS Physicians: maximum of 1.0 AMA PRA Category 1 Credit ABIM MOC: maximum of 1.0 Medical Knowledge MOC point(s) Registered Nurses: 1.0 Nursing contact hour Released: December 4, 2020 Expired: December 31, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue